OPTIMIZING ORGAN PERFUSION: MANAGEMENT OF THE POTENTIAL DECEASED DONOR

Abstract

Optimal management for a potential deceased donor is crucial to the transplantation process, as it significantly influences both the quantity and quality of organs available for transplantation. Upon determination of death by neurological criteria (DNC), the body undergoes significant physiological alterations, including hemodynamic instability, endocrine failure, poor thermoregulation, hypernatremia, metabolic acidosis, and coagulopathy. The primary objective of donor management is to restore homeostasis by ensuring sufficient blood flow and oxygen supply to the organs, thereby mitigating ischemic harm and enhancing the likelihood of transplant survival.

Hemodynamic stability remains a central determinant of organ viability in the potential deceased donor. Targeting key hemodynamic and vital parameters through goal-directed therapy is essential for maintaining adequate organ perfusion. Continuous or intermittent monitoring—using available techniques such as invasive arterial pressure, central venous pressure, or advanced cardiac output monitoring—guides individualized therapy. Fluid resuscitation should primarily rely on balanced crystalloids, among which Ringer’s or Plasma-Lyte solutions are preferred over normal saline due to their favorable acid–base profile and reduced risk of hyperchloremic acidosis. The use of colloids is generally discouraged; however, in cases unresponsive to crystalloids, albumin may be considered. When adequate perfusion cannot be achieved with fluids alone, vasopressors and inotropes should be titrated based on clinical response. Norepinephrine is preferred for maintaining mean arterial pressure due to its predictable α-adrenergic effect, while dobutamine is the inotrope of choice in donors with myocardial dysfunction, enhancing contractility and cardiac output. Vasopressin may be added as an adjunct agent because of its stable vasomotor action, absence of cardiotoxicity, and catecholamine-sparing effect, particularly in donors with diabetes insipidus. Low-dose dopamine (≤3μg/kg/min) may be considered selectively in hemodynamically stable donors, as some studies suggest a potential renal-protective and immunomodulatory benefit; however, its use is controversial and not routinely recommended due to the risk of arrhythmias and metabolic instability.

Endocrine replacement therapy, including methylprednisolone (15 mg/kg), triiodothyronine (T3), and desmopressin (DDAVP), is incorporated in several donor management protocols to enhance hemodynamic stability, preserve hormonal balance, and attenuate the inflammatory cascade. Desmopressin is preferred for the treatment of diabetes insipidus due to its selective V₂-receptor activity, effective antidiuretic action, and lack of vasoconstrictive or cardiotoxic effects. While the routine use of thyroid hormone supplementation remains debated, corticosteroids play a crucial role in restoring vascular responsiveness, improving cardiac output, and reducing cytokine-mediated inflammation following brain death.

Protective mechanical ventilation (tidal volume 6–8 mL/kg, PEEP 8–10 cmH₂O, PaO₂/FiO₂ >300) should be maintained to prevent barotrauma and volutrauma. Early administration of corticosteroids and bronchodilators (salbutamol or terbutaline) helps improve alveolar fluid clearance and lung preservation. Prevention of hypothermia through active warming (maintaining core temperature above 35°C) reduces arrhythmias, coagulopathy, and metabolic acidosis. Nutritional support, parenteral or controlled enteral feeding, should continue up to the time of organ retrieval to maintain metabolic balance and prevent catabolism.

Continuous, multidisciplinary coordination among intensivists, anesthesiologists, and transplant coordinators is vital for donor stabilization and optimal organ perfusion. Any delay or inconsistency in donor management increases the risk of secondary ischemic injury and reduces the number of viable grafts. In modern transplant medicine, maintaining perfusion in the deceased donor is not merely the continuation of intensive care but a deliberate strategy to preserve organ function. Implementation of standardized donor management algorithms, close monitoring of oxygenation and hemodynamic parameters, and targeted hormonal stabilization have proven essential for achieving successful multi-organ procurement and improving post-transplant outcomes.